Walmart agrees $50 million settlement ending DOJ opioid dispensing lawsuit

By ··2 min read

The Department of Justice and the Drug Enforcement Administration announced a $50 million settlement with Walmart Inc. resolving allegations that its pharmacies filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act. Walmart also entered a memorandum of agreement with the DEA imposing new compliance obligations and did not admit liability.

Walmart Inc. has agreed to pay $50 million to resolve Department of Justice allegations that its pharmacies illegally filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act. The Justice Department and the Drug Enforcement Administration announced the settlement on August 28, 2026. Alongside the payment, Walmart has signed a memorandum of agreement with the DEA setting out additional compliance obligations for its pharmacy operations.

The government first sued Walmart on December 22, 2020, in the US District Court for the District of Delaware. It alleged that from June 26, 2013, Walmart filled invalid prescriptions through the knowing actions of its pharmacists and members of its corporate compliance team. According to the department, compliance staff knew certain prescribers were operating as pill mills but allowed their prescriptions to be filled. Pharmacists flagged problem prescribers through thousands of refusal-to-fill forms, and the compliance function is alleged to have prioritised other objectives over acting on them. In March 2024, Judge Colm Connolly narrowed the case, dismissing claims that Walmart failed to report suspicious prescriptions to the DEA.

Walmart did not admit liability. A company spokesperson said Walmart was pleased to resolve the matter, and described the $50 million amount as immaterial in a regulatory filing. The Justice Department stated that the claims resolved are allegations only and that no liability has been determined.

The figure is modest against the scale of the original case, under which Walmart potentially faced billions of dollars in civil penalties. It is separate from the roughly $3.1 billion framework Walmart agreed in 2022 to settle opioid claims brought by state and local governments. Under the new DEA memorandum of agreement, Walmart must establish a hotline for employees and patients to report suspected illegal dispensing, proactively monitor dispensing patterns across its pharmacies, and create a process for evaluating prescribers suspected of illegal prescribing.

A joint stipulation of dismissal was filed in federal court in Wilmington, Delaware, on August 27. The case was handled by the Civil Division and US Attorney's Offices for the District of Delaware, the Eastern District of North Carolina, the Middle District of Florida and the Eastern District of New York. Walmart's pharmacies will now operate under the obligations set out in the DEA memorandum of agreement.

Cite this report

The Precedent. "Walmart agrees $50 million settlement ending DOJ opioid dispensing lawsuit." September 15, 2026. https://theprecedent.org/article/walmart-agrees-50-million-settlement-ending-doj-opioid-dispensing-lawsuit